NO994397L - FremgangsmÕte ved integrering av gener ved spesifikke seter i pattedyrceller via homolog rekombinasjon samt vektorer for utförelse av fremgangsmÕten - Google Patents

FremgangsmÕte ved integrering av gener ved spesifikke seter i pattedyrceller via homolog rekombinasjon samt vektorer for utförelse av fremgangsmÕten

Info

Publication number
NO994397L
NO994397L NO994397A NO994397A NO994397L NO 994397 L NO994397 L NO 994397L NO 994397 A NO994397 A NO 994397A NO 994397 A NO994397 A NO 994397A NO 994397 L NO994397 L NO 994397L
Authority
NO
Norway
Prior art keywords
homologous recombination
via homologous
vectors
mammalian cells
cells via
Prior art date
Application number
NO994397A
Other languages
English (en)
Norwegian (no)
Other versions
NO994397D0 (no
Inventor
Mitchell E Reff
Richard Spence Barnett
Karen Retta Mclachlan
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26697516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994397(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/819,866 external-priority patent/US5830698A/en
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of NO994397D0 publication Critical patent/NO994397D0/no
Publication of NO994397L publication Critical patent/NO994397L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO994397A 1997-03-14 1999-09-10 FremgangsmÕte ved integrering av gener ved spesifikke seter i pattedyrceller via homolog rekombinasjon samt vektorer for utförelse av fremgangsmÕten NO994397L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/819,866 US5830698A (en) 1997-03-14 1997-03-14 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US09/023,715 US5998144A (en) 1997-03-14 1998-02-13 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
PCT/US1998/003935 WO1998041645A1 (en) 1997-03-14 1998-03-09 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same

Publications (2)

Publication Number Publication Date
NO994397D0 NO994397D0 (no) 1999-09-10
NO994397L true NO994397L (no) 1999-11-09

Family

ID=26697516

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994397A NO994397L (no) 1997-03-14 1999-09-10 FremgangsmÕte ved integrering av gener ved spesifikke seter i pattedyrceller via homolog rekombinasjon samt vektorer for utförelse av fremgangsmÕten

Country Status (21)

Country Link
US (3) US6413777B1 (cg-RX-API-DMAC7.html)
EP (1) EP0981637B1 (cg-RX-API-DMAC7.html)
JP (1) JP4128227B2 (cg-RX-API-DMAC7.html)
CN (1) CN1175111C (cg-RX-API-DMAC7.html)
AT (1) ATE296356T1 (cg-RX-API-DMAC7.html)
AU (1) AU737155B2 (cg-RX-API-DMAC7.html)
BR (1) BR9808584A (cg-RX-API-DMAC7.html)
CA (1) CA2283740C (cg-RX-API-DMAC7.html)
CZ (1) CZ293355B6 (cg-RX-API-DMAC7.html)
DE (1) DE69830312T2 (cg-RX-API-DMAC7.html)
ES (1) ES2242997T3 (cg-RX-API-DMAC7.html)
ID (1) ID24565A (cg-RX-API-DMAC7.html)
IL (1) IL131746A0 (cg-RX-API-DMAC7.html)
IN (1) IN189732B (cg-RX-API-DMAC7.html)
NO (1) NO994397L (cg-RX-API-DMAC7.html)
PL (1) PL191251B1 (cg-RX-API-DMAC7.html)
PT (1) PT981637E (cg-RX-API-DMAC7.html)
RO (1) RO120148B1 (cg-RX-API-DMAC7.html)
RU (1) RU2004107694A (cg-RX-API-DMAC7.html)
TW (1) TWI232239B (cg-RX-API-DMAC7.html)
WO (1) WO1998041645A1 (cg-RX-API-DMAC7.html)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
RO120148B1 (ro) * 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
WO1999029902A1 (en) 1997-12-08 1999-06-17 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
US6316253B1 (en) 1999-11-01 2001-11-13 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
DK1297170T3 (en) * 2000-06-23 2016-03-14 Novozymes As A process for stable chromosomal integration of multiple copies of the genes
EP2412242A3 (en) 2001-07-05 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
HUP0402164A3 (en) 2001-11-16 2010-01-28 Biogen Idec Inc Polycistronic expression of antibodies
US7164056B2 (en) * 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20040170614A1 (en) * 2002-10-30 2004-09-02 Gail Bishop Somatic cell gene targeting vectors and methods of use thereof
EA013225B1 (ru) * 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
DE10303937A1 (de) * 2003-01-31 2004-08-12 Icon Genetics Ag Pflanzentransformation mit Assemblierung einer gewünschten Sequenz in Vivo
ATE426672T1 (de) * 2003-01-31 2009-04-15 Icon Genetics Gmbh Pflanzentransformation mit in-vivo-zusammenbau einer eigenschaft
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP5416338B2 (ja) * 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
AU2004252170B2 (en) * 2003-06-27 2011-01-27 Biogen Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
ES2374526T3 (es) 2003-09-04 2012-02-17 Medarex, Inc. Vector de expresión.
US8030833B2 (en) * 2003-09-19 2011-10-04 The Board Of Trustees Of The University Of Illinois Electron emission device incorporating free standing monocrystalline nanowires
US7344753B2 (en) * 2003-09-19 2008-03-18 The Board Of Trustees Of The University Of Illinois Nanostructures including a metal
US7935862B2 (en) * 2003-12-02 2011-05-03 Syngenta Participations Ag Targeted integration and stacking of DNA through homologous recombination
CA2554054C (en) 2004-01-20 2013-06-04 Merus B.V. Mixtures of binding proteins
BRPI0512500A (pt) 2004-06-24 2008-03-11 Biogen Idec Inc tratamento ou condições envolvendo desmielinação
EP2053408B1 (en) 2004-07-20 2012-03-07 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
EP2329714A1 (en) 2004-08-03 2011-06-08 Biogen Idec MA Inc. Influence of TAJ in the neuronal functions
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
KR20070100346A (ko) 2005-01-05 2007-10-10 바이오겐 아이덱 엠에이 인코포레이티드 크립토 결합 분자
CN100381573C (zh) * 2005-04-14 2008-04-16 北京天广实生物技术有限公司 快速构建目标基因高表达的哺乳动物细胞株的体系和方法
RS53058B (sr) 2005-07-08 2014-04-30 Biogen Idec Ma Inc. Sp35 antitela i njihova primena
NZ565711A (en) * 2005-08-09 2011-10-28 Revivicor Inc Transgenic ungulates expressing a porcine CTLA4 peptide fused to an immunoglobulin
JP2009517340A (ja) 2005-11-04 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ドーパミン作動性ニューロンの神経突起成長および生存を促進するための方法
NZ569428A (en) 2005-12-02 2012-11-30 Biogen Idec Inc Treatment of conditions involving demyelination with a Sp35 antagonist
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
CN103215293B (zh) 2006-01-27 2015-10-28 比奥根Ma公司 Nogo受体拮抗剂
SI2436696T1 (sl) 2007-01-05 2017-10-30 University Of Zurich Anti-beta-amiloidno protitelo in načini njegove uporabe
CA2674603C (en) 2007-01-09 2016-03-29 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EA017403B1 (ru) 2007-02-02 2012-12-28 Байоджен Айдек Эмэй Инк. Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
CA2708776A1 (en) * 2007-12-10 2009-06-18 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
KR102362774B1 (ko) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
EA030826B1 (ru) 2008-12-19 2018-10-31 Панима Фармасьютикалз Аг ЧЕЛОВЕЧЕСКИЕ АУТОАНТИТЕЛА ПРОТИВ α-СИНУКЛЕИНА
EP2382238A1 (en) 2008-12-31 2011-11-02 Biogen Idec MA Inc. Anti-lymphotoxin antibodies
CA2756186A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
JP4998814B2 (ja) 2009-10-01 2012-08-15 Ｔｏｔｏ株式会社 Ｄｎａ構築物およびそれを用いた組み換えｃｈｏ細胞の製造方法
ES2641920T3 (es) 2010-03-31 2017-11-14 Ablexis, Llc Ingeniería genética de animales no humanos para la producción de anticuerpos quiméricos
SG184903A1 (en) * 2010-04-30 2012-11-29 Temasek Life Sciences Lab Ltd Fragment switch: a reverse genetic approach
EA201291482A1 (ru) 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
PT2627672T (pt) 2010-10-11 2018-11-16 Univ Zuerich Anticorpos anti-tau humanos
DK2640743T3 (en) 2010-11-16 2017-01-23 Excelimmune Inc PROCEDURES FOR THE PREPARATION OF RECOMBINANT PROTEINS
JP5209693B2 (ja) * 2010-12-10 2013-06-12 ロンザ・バイオロジクス・ピーエルシー Ｃｈｏ細胞において組換えタンパク質を発現する方法
JP6067575B2 (ja) 2010-12-17 2017-01-25 ニューリミューン ホールディング エイジー ヒト抗ｓｏｄ１抗体
ES2699801T3 (es) 2011-06-23 2019-02-12 Biogen Int Neuroscience Gmbh Moléculas de unión anti-alfa sinucleína
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
ES2740749T3 (es) 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
KR101904508B1 (ko) 2012-04-25 2018-10-04 리제너론 파마슈티칼스 인코포레이티드 큰 표적화 벡터를 사용한 뉴클레아제-중재된 표적화
US10174331B2 (en) 2012-05-07 2019-01-08 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
EP2849787A4 (en) 2012-05-14 2016-06-15 Biogen Ma Inc LINGO-2 ANTAGONISTS FOR THE TREATMENT OF DISEASES INVOLVING ENGINE NEURONS
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
MX2015004436A (es) 2012-10-09 2015-06-24 Biogen Idec Inc Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
AU2013361107B2 (en) 2012-12-21 2018-08-23 Biogen International Neuroscience Gmbh Human anti-tau antibodies
US9771413B2 (en) 2012-12-31 2017-09-26 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
PL2956477T5 (pl) 2013-02-15 2024-05-27 Bioverativ Therapeutics Inc. Zoptymalizowany gen czynnika viii
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
CN107074937B (zh) 2014-07-29 2021-07-27 神经免疫控股公司 人源抗亨廷顿蛋白(htt)抗体及其用途
AU2015326911C1 (en) 2014-09-30 2025-12-18 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (DPRs) antibody
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
CN106191040B (zh) * 2015-04-30 2021-09-14 杭州菁因康生物科技有限公司 基因打靶方法
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
RS63548B1 (sr) 2016-02-01 2022-09-30 Bioverativ Therapeutics Inc Optimizovani geni faktora viii
WO2017214376A1 (en) 2016-06-10 2017-12-14 Elwha Llc Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
MA45668A (fr) 2016-07-13 2019-05-22 Biogen Ma Inc Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
KR20250040746A (ko) 2017-08-09 2025-03-24 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
WO2019210054A1 (en) 2018-04-27 2019-10-31 Biogen Ma Inc. Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody
LT3793588T (lt) 2018-05-18 2025-06-25 Bioverativ Therapeutics Inc. Hemofilijos a gydymo būdai
KR102848349B1 (ko) 2018-06-04 2025-08-21 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
CN110607326B (zh) * 2018-06-15 2022-11-29 江苏省农业科学院 非强启动式的外源基因表达法及其在具有毒性的目标蛋白表达中的应用
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
JP7549582B2 (ja) * 2018-10-01 2024-09-11 ロンザ リミテッド 予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法
SG11202108560RA (en) 2019-02-13 2021-09-29 Brigham & Womens Hospital Inc Anti-peripheral lymph node addressin antibodies and uses thereof
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
JP2023516028A (ja) 2020-02-28 2023-04-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 多重特異性抗体を介したトランスフォーミング増殖因子ベータスーパーファミリーシグナル伝達の選択的調節
BR112022026127A2 (pt) 2020-06-24 2023-01-17 Bioverativ Therapeutics Inc Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
WO2023028455A1 (en) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Closed-end dna production with inverted terminal repeat sequences
TW202323274A (zh) 2021-08-23 2023-06-16 美商百歐維拉提夫治療公司 優化因子viii基因
AU2022355088A1 (en) 2021-09-30 2024-05-16 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2025104243A1 (en) 2023-11-15 2025-05-22 Neurimmune Ag Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1991006667A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
AU4401993A (en) * 1992-06-04 1993-12-30 Exemplar Corporation Insertion of heterologous dna outside of known chromosomal genes
MX9305183A (es) * 1992-08-27 1994-05-31 Us Agriculture Intron portatil, molecula de adn genomico viral, virus vivo y vacuna que los contiene y metodo para su obtencion.
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
RO120148B1 (ro) * 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere

Also Published As

Publication number Publication date
CN1175111C (zh) 2004-11-10
ID24565A (id) 2000-07-27
EP0981637A1 (en) 2000-03-01
US7235360B2 (en) 2007-06-26
US6841383B2 (en) 2005-01-11
US20040166528A1 (en) 2004-08-26
IL131746A0 (en) 2001-03-19
AU737155B2 (en) 2001-08-09
BR9808584A (pt) 2000-05-23
JP2001516221A (ja) 2001-09-25
NO994397D0 (no) 1999-09-10
CZ293355B6 (cs) 2004-04-14
RU2004107694A (ru) 2005-08-27
TWI232239B (en) 2005-05-11
US20020192820A1 (en) 2002-12-19
AU6443598A (en) 1998-10-12
DE69830312T2 (de) 2006-02-02
ES2242997T3 (es) 2005-11-16
EP0981637B1 (en) 2005-05-25
WO1998041645A1 (en) 1998-09-24
CZ316299A3 (cs) 2000-02-16
US6413777B1 (en) 2002-07-02
CA2283740A1 (en) 1998-09-24
PL335695A1 (en) 2000-05-08
CA2283740C (en) 2006-06-27
ATE296356T1 (de) 2005-06-15
IN189732B (cg-RX-API-DMAC7.html) 2003-04-19
CN1255166A (zh) 2000-05-31
RO120148B1 (ro) 2005-09-30
DE69830312D1 (de) 2005-06-30
PT981637E (pt) 2005-09-30
JP4128227B2 (ja) 2008-07-30
PL191251B1 (pl) 2006-04-28

Similar Documents

Publication Publication Date Title
NO994397L (no) FremgangsmÕte ved integrering av gener ved spesifikke seter i pattedyrceller via homolog rekombinasjon samt vektorer for utförelse av fremgangsmÕten
MY137837A (en) Novel method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
DK1097211T3 (da) Ekspression af eukaryote peptider i planteplastider
HUP9700428A2 (hu) Célsejtspecifikus vektorok gének beépítésére, a vektorokat tartalmazó gyógyászati készítmények és azok alkalmazása
WO1999015682A3 (en) Gene silencing materials and methods
DK159188D0 (da) Ekspressionsvektor, der er i stand til at styre ekspression af heterologe gener eller cdna i gaer, gaervaertscelle samt fremgangsmaade til oeget produktion af proteiner i gaervaertsceller
BR8200191A (pt) Celula viva renina preprorrenina prorrenina processo para obter expressao de preporrenina prorrenina e renina gene de prorrenina preprorrenina e renina e coli material dna recombinador saccharomyces cerevisiae polipetidio processo para exprimir um gene
NO20031897D0 (no) Fremgangsmåte for modifisering av eukaryotiske celler
MX9709317A (es) Cromosomas sinteticos de mamifero y metodos para su construccion.
ATE404684T1 (de) Methoden und zusammensetzungen zur transformation von zellen
NO964445D0 (no) DNA-sekvens, vektor, vertscelle og fremgangsmåte for transfeksjon av hematopoeseceller med eksogen DNA
DE69831417D1 (de) Duale selektionkassette und sie enthaltende plasmide
EP1200557A4 (en) PROCESS FOR THE MANUFACTURE OF ARTIFICIAL PLANT CHROMOSOMES
Van Loon et al. Formation of extrachromosomal circular DNA in HeLa cells by nonhomologous recombination
TR199802503A2 (xx) Endojen gen aktivasyonu i�in h�crelerin optimizasyonu.
ATE244311T1 (de) Expressionssystem von antikörpern bei homologischer rekombinierung in murinezellen
ATE295888T1 (de) Genfallen-konstrukt zur identifizierung und isolierung von genen
WO1999021976A3 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
Yoneda et al. Cloning of a foreign gene coding for α-amylase in Bacillussubtilis
WO2001079512A3 (en) Vector and method for targeted replacement and disruption of an integrated dna sequence
DE3684017D1 (de) Vielfach amplifizierbare vektoren fuer hohe expression exogener dns.
ATE49998T1 (de) Klonierungsvektoren, die eine restriktionsstellenbank enthalten und deren herstellung.
ATE259421T1 (de) Dna-virus-vektoren und verfahren zu ihrer herstellung
WO1994016074A3 (en) High molecular weight b-cell growth factor: interleukin-14
WO2000037682A8 (en) Method for augmenting expression of a foreign gene

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application